PureTech Health (PRTC)

Down
Share Price:
403.00p
Market Cap:
1,152.17m
Change Today:
-9.50p
Sector:
Pharma and Biotech

PureTech appoints George Farmer as new finance chief

By Josh White

Date: Tuesday 05 Jan 2021

LONDON (ShareCast) - (Sharecast News) - Clinical-stage biotherapeutics company PureTech Health announced on Tuesday that George Farmer has been appointed chief financial officer.
The FTSE 250 firm said that, as a key member of its senior leadership team, Dr Farmer would be responsible for all aspects of its finances, including capital markets strategy and execution, strategic and financial planning, and financial reporting.

"We are delighted to welcome George to the senior leadership team as we are poised to build on the momentum of the past year," said founder and chief executive officer Daphne Zohar.

"This is an important moment for PureTech, as we recently initiated three clinical trials based on programs from our wholly-owned pipeline and expanded our presence with the Nasdaq Global Market listing.

"We believe that George's depth of experience will be very helpful as we share the PureTech story with a broader community of investors."

Dr Farmer was joining PureTech from BMO Capital Markets, where he completed a 15-year career as a senior biotechnology equity analyst, providing in-depth sector research for institutional investor clients.

Prior to that, he served as chief executive officer of the privately-held Cortice Biosciences, which was focussed on the clinical development of therapies for brain malignancies and neurodegenerative diseases.

Dr Farmer also served as vice-president of corporate development at Synta Pharmaceuticals, a publicly-traded company developing cancer therapeutics.

He was a postdoctoral fellow at Sloan Kettering Cancer Center and University of California San Francisco after receiving his Ph.D. in biological sciences from Columbia University and a BA from Dartmouth College.

"PureTech has built a leadership position in the science of the brain-immune-gut axis, which has led to the discovery and development of novel medicines," said Dr Farmer.

"I am particularly intrigued by the potential of LYT-100 for treating multiple fibrotic diseases and LYT-200 as a potential new cancer immunotherapeutic.

"Just as impressive is the track record of management, which has developed a deep therapeutic pipeline both internally and through the company's founded entities."

At 0924 GMT, shares in PureTech Health were up 0.19% at 404.26p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

PRTC Market Data

Currency UK Pounds
Price 403.00p
Change Today -9.50p
52 Week High 425.50p
52 Week Low 221.50p
Volume 124,817
Shares Issued 285.90m
Market Cap 1,152.17m

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. empty sector
Price Trend
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Income
Not Available
Growth
market
  1. empty market
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. empty sector
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Price Chg 6m
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. empty sector
P/E
market
  1. empty market
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. empty sector
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. half market star
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star
Dividend Yield
Not Available
EPS Growth
market
  1. empty market
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. empty sector
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Operating Margin
market
  1. empty market
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. half sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector

What The Brokers Say

Strong Buy 5
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 5
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.